Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity

Tumor Biology

Volumn 24, Issue 4, 2003, Pages 185-188

  Miret, Carlos ^a   Molina, Rafael ^a   Filella, Xavier ^a   García Carrasco, Mario ^a   Claver, Gisela ^a   Ingelmo, Miguel ^a   Ballesta, Antonio ^a   Font, José ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Apoptosis; Cytokines; Oncogenes; p53; Systemic lupus erythematosus

Indexed keywords

CYTOKINE; DNA ANTIBODY; FAS ANTIGEN; INTERLEUKIN 10; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0345490927     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074428     Document Type: Article

References (29)

1. Gmelig-Meyling F, Dawisha S, Steinberg AD: Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus. J Exp Med 1992;175:297-300.
2. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL: Lymphocyte apoptosis in systemic lupus erythematosus: Relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999;8:508-513.
3. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
4. Wang M, Dong Y, Huang S: Study of the association between tumor necrosis factor alpha gene polymorphism and systemic lupus erythematosus (in Chinese). Zhonghua Nei Ke Za Zhi 1999;38:393-396.
5. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, Radda I, Smole JS, Graninger WB: Increased bioactive TNF in human systemic lupus erythematosus: Associations with cell death. Lupus 2002;11:102-108.
6. Miret C, Font J, Molina R, García-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M: Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001;21:3053-3059.
7. Rose LM, Latchman DS, Isenberg DA: Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: A review. Br J Rheumatol 1997;36:158-163.
8. Korsmeter SJ: Bcl-2: A repressor of lymphocyte death. Immunol Today 1992;13:285-288.
9. Mehrian R, Quismorio FP Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, Gauderman WJ, Morrison J, Brautbar C, Jacob CO: Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41:596-602.
10. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM: Interleukin-10 rescues T cells from apoptotic cell death: Association with an upregulation of Bcl-2. Immunology 1997;92:1-5.
11. Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, Finke J: Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 1996;88:2549-2558.
12. Levy Y, Brouet JC: Interleukin-10 prevents spontaneous death of germinal center B cells by induction of bcl-2 protein. J Clin Invest 1994;93:424-428.
13. Hase K, Tani K, Shimizu T, Ohmoto Y, Matsushima K, Sone S: Increased CCR4 expression in active systemic lupus erythematosus. J Leukoc Biol 2001;70:749-755.
14. Liu Y, Yin P, Zhao X: Clinical significance and expression of Bcl-2 protein in patients with systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 1999;38:94-97.
15. Houssiau FA, Lefebvre C, Van den Berghe M, Lambert M, Devogelaer JP, Renauld JC: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995;4:393-395.
16. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH: Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-288.
17. Miret C, Font J, Molina R, García-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M: Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity. Anticancer Res 1999;19:3073-3076.
18. Alvarado-de la Barrera C, Alcocer-Varela J, Richaud-Patin Y, Alarcon-Segovia D, Llorente L: Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients. Scand J Immunol 1998;48:551-556.
19. Herkel J, Erez-Alon N, Mimran A, Wolkowicz R, Harmelin A, Ruiz P, Rotter V, Cohen IR: Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. Eur J Immunol 2000;30:977-984.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for classification of SLE. Arthritis Rheum 1982; 25:1271-1272.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLE-DAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640.
22. McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB: Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994;37:559-567.
23. Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB: Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-1737.
24. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K, Koike T: Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997;107:89-95.
25. Migita K, Eguchi K, Kawabe Y, Nakamura T, Shirabe S, Tsukada T, Ichinose Y, Nakamura H, Nagataki S: Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 1997;63:583-587.
26. Zhang W, Hu G, Estey E, Hester J, Deisseroth A: Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992;7:1645-1647.
27. Wu J, Wang M, Li X, Sheng Y: Conformation changes of p53 proteins in regulation of murine T lymphocyte proliferation. Cell Mol Res 1993;39:27-31.
28. Kuhn HM, Kromminga A, Flammann HT, Frey M, Layer P, Arndt R: p53 autoantibodies in patients with autoimmune diseases: A quantitative approach. Autoimmunity 1999;31:229-235.
29. Herkel J, Mimran A, Erez N, Kam N, Lohse AW, Marker-Hermann E, Rotter V, Cohen IR: Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J Autoimmun 2001;17:63-69.